Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings

  • Kite, a Gilead Sciences Inc GILD company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). 
  • The analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with a consistent safety profile observed since the two-year analysis. 
  • In the Phase 2 treated patient cohort (n=55), the median follow-up was 38.8 months. The OS rate at 36.0 months was 47.1%, with a median OS of 26.0 months among all treated Phase 2 patients (n=55) and 38.9 months in patients with complete remission (CR) or complete remission with incomplete hematologic recovery (CRi; n=39). 
  • Overall CR rate (CR + CRi), CR, and subsequent allogeneic stem cell transplant (alloSCT) rates remained unchanged since the prior data cut at 71%, 56%, and 20%, respectively. 
  • Median relapse-free survival (RFS) was censored and not censored at subsequent alloSCT at 11.6 and 11.7 months, respectively.
  • At the data cutoff, 36% of patients (28) were still alive, with a median OS of 25.6 months.
  • Price Action: GILD shares are up 0.46% at $86.06 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!